International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study. Issue 4 (19th July 2021)

• Record Type: Journal Article
• Authors: Araghi, Marzieh; Fidler-Benaoudia, Miranda; Arnold, Melina; Rutherford, Mark; Bardot, Aude; Ferlay, Jacques; Bucher, Oliver; De, Prithwish; Engholm, Gerda; Gavin, Anna; Kozie, Serena; Little, Alana; Møller, Bjørn; St Jacques, Nathalie; Tervonen, Hanna; Walsh, Paul; Woods, Ryan; O'Connell, Dianne L; Baldwin, David; Elwood, Mark; Siesling, Sabine; Bray, Freddie; Soerjomataram, Isabelle
• Other Names: author non-byline.; Little Alana author non-byline.; Eckstrand Angela author non-byline.; Gavin Anna author non-byline.; Zhang Bin author non-byline.; Møller Bjørn author non-byline.; McClure Carol author non-byline.; Thomas Rebecca author non-byline.; Marano Connie author non-byline.; Bertrand Christine author non-byline.; Jackson Christopher author non-byline.; Austin Claire author non-byline.; Gavin David author non-byline.; Morrison David S author non-byline.; Fitzpatrick Deirdre author non-byline.; Turner Donna author non-byline.; Huws Dyfed author non-byline.; Kumar Eshwar author non-byline.; Noonan Gail author non-byline.; Porter Geoff author non-byline.; Engholm Gerda author non-byline.; Lockwood Gina author non-byline.; Musto Grace author non-byline.; Bolesnikov Grlica author non-byline.; Ruel Guillaume author non-byline.; Tervonen Hanna author non-byline.; Elkader Hazem Abd author non-byline.; Stuart-Panko Heather author non-byline.; Warlow Janet author non-byline.; Poole Jason author non-byline.; Spinelli John author non-byline.; Shack Lorraine author non-byline.; Sandford Louise author non-byline.; Jerm Marianne Brenn author non-byline.; MacIntyre Maureen author non-byline.; St-Jacques Nathalie author non-byline.; Bucher Oliver author non-byline.; Walsh Paul author non-byline.; De Prithwish author non-byline.; Agnihotram Raman author non-byline.; Trevithick Richard author non-byline.; Carle Rory author non-byline.; Woods Ryan author non-byline.; Vernon Sally author non-byline.; Kozie Serena author non-byline.; Ryan Susan author non-byline.; Evans Sue author non-byline.; author non-byline.; O'Connell Dianne author non-byline.; Eden Michael author non-byline.; Elwood Mark author non-byline.; Siesling Sabine author non-byline.; author non-byline.; Guhan Anur author non-byline.; Finley Christian author non-byline.; McCaughan Brian author non-byline.; Baldwin David author non-byline.; Jakobsen Erik author non-byline.; Williamson Ian author non-byline.; Lester Jason author non-byline.; McAleese Jonathan author non-byline.; Kolbeck Karl author non-byline.; Peake Mick author non-byline.; Brustugun Odd Terje author non-byline.; Dawkins Paul author non-byline.; Anderson Wendy author non-byline.;
• Is Part Of: Thorax. Volume 77:Issue 4(2022)
• Page Start: 378
• Page End: 390
• Publication Date: 2021-07-19
• Subjects: Histology/Cytology -- Lung Cancer -- Non-Small Cell Lung Cancer -- Small Cell Lung Cancer; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2020-216555
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: Lung cancer has a poor prognosis that varies internationally when assessed by the two major histological subgroups (non-small cell (NSCLC) and small cell (SCLC)). Method: 236 114 NSCLC and 43 167 SCLC cases diagnosed during 2010–2014 in Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK were included in the analyses. One-year and 3-year age-standardised net survival (NS) was estimated by sex, histological type, stage and country. Results: One-year and 3-year NS was consistently higher for Canada and Norway, and lower for the UK, New Zealand and Ireland, irrespective of stage at diagnosis. Three-year NS for NSCLC ranged from 19.7% for the UK to 27.1% for Canada for men and was consistently higher for women (25.3% in the UK; 35.0% in Canada) partly because men were diagnosed at more advanced stages. International differences in survival for NSCLC were largest for regional stage and smallest at the advanced stage. For SCLC, 3-year NS also showed a clear female advantage with the highest being for Canada (13.8% for women; 9.1% for men) and Norway (12.8% for women; 9.7% for men). Conclusion: Distribution of stage at diagnosis among lung cancer cases differed by sex, histological subtype and country, which may partly explain observed survival differences. Yet, survival differences were also observed within stages, suggesting that quality of treatment, healthcare system factors and prevalence of comorbid conditions may also influence survival. Other possible explanations include differences in data collection practice, as well as differences in histological verification, staging and coding across jurisdictions.